Welcome international healthcare professionals

This site is no longer supported and will not be updated with new content. You are welcome to browse and download all content already included in the site. Please note you will have to register your email address to access the site.

You are here

Progress in acute myeloid leukemia

Clinical Lymphoma Myeloma and Leukemia

Abstract

Significant progress has been made in the treatment of acute myeloid leukemia (AML). Steady gains in clinical research and a renaissance of genomics in leukemia have led to improved outcomes. The recognition of tremendous heterogeneity in AML has allowed individualized treatments of specific disease entities within the context of patient age, cytogenetics, and mutational analysis. The following is a comprehensive review of the current state of AML therapy and a roadmap of our approach to these distinct disease entities.

Key Words: AML Induction, Hypomethylating, FLT3.

Footnotes

Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX

Address Correspondence, Tapan M. Kadia, MD , Department of Leukemia, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Box 428, Houston, TX 77030, Phone: (713) 792-7305.